Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences logo
$156.04 -1.15 (-0.73%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$156.99 +0.95 (+0.61%)
As of 10/23/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
6
Buy
23

Based on 29 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 6 have given a hold rating, and 23 have given a buy rating for GILD.

Consensus Price Target

$159.81
2.42% Upside
According to the 29 analysts' twelve-month price targets for Gilead Sciences, the average price target is $159.81. The highest price target for GILD is $185.00, while the lowest price target for GILD is $126.00. The average price target represents a forecasted upside of 2.42% from the current price of $156.04.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
23 Buy rating(s)
23 Buy rating(s)
25 Buy rating(s)
20 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$159.81$158.78$158.30$122.61
Forecasted Upside2.42% Upside5.20% Upside21.28% Upside1.38% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesHealthcare CompaniesBroader Market
Consensus Rating Score
2.79
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside2.42% Upside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent GILD News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Akash Tewari
4 of 5 stars
Reiterated RatingBuy$185.00+17.69%
10/20/2026
Bank of America Corporation logo
Bank of America
4 of 5 stars
Tim Anderson
Tim Anderson
4 of 5 stars
Boost TargetBuy$168.00 ➝ $172.00+12.37%
10/8/2026
Brian Abrahams
Brian Abrahams
5 of 5 stars
Boost TargetSector Perform$123.00 ➝ $126.00-13.44%
10/8/2026Reiterated RatingOverweight$155.00+5.55%
10/7/2026Boost TargetBuy$150.00 ➝ $158.00+7.17%
10/7/2026Boost TargetOverweight$160.00 ➝ $170.00+15.00%
10/7/2026Lower TargetOverweight$165.00 ➝ $163.00+10.32%
9/29/2026 DowngradeStrong-Buy ➝ Hold
9/14/2026 UpgradeHold (C-) ➝ Hold (C)
9/10/2026Boost TargetBuy$155.00 ➝ $175.00+20.61%
8/5/2026Reiterated RatingBuy$170.00+25.69%
7/29/2026Lower TargetEqual Weight$155.00 ➝ $145.00+7.95%
7/21/2026DowngradeOutperform ➝ Market Perform$146.00 ➝ $127.00-4.66%
5/20/2026UpgradeHold ➝ Buy$165.00+26.44%
5/19/2026 Lower TargetOutperform$161.00 ➝ $150.00+14.65%
5/11/2026 Lower Target$170.00 ➝ $167.00+25.18%
4/17/2026 Boost TargetNeutral$125.00 ➝ $130.00-5.41%
4/13/2026Boost TargetBuy$156.00 ➝ $165.00+19.83%
2/19/2026 Boost TargetBuy$135.00 ➝ $165.00+9.18%
2/18/2026 Boost TargetOutperform$140.00 ➝ $170.00+11.30%
2/12/2026Boost TargetOutperform$155.00 ➝ $170.00+9.11%
2/11/2026Reiterated RatingOutperform$160.00+3.14%
2/11/2026 Boost TargetOutperform$128.00 ➝ $165.00+5.91%
2/11/2026 Boost TargetBuy$135.00 ➝ $155.00-0.51%
2/11/2026Boost TargetBuy$145.00 ➝ $160.00+2.70%
2/11/2026Boost TargetOverweight$150.00 ➝ $165.00+12.07%
2/11/2026Boost TargetSector Outperform$140.00 ➝ $177.00+20.22%
1/26/2026Boost TargetBuy$145.00 ➝ $155.00+12.54%
1/26/2026Boost TargetOutperform$135.00 ➝ $150.00+10.35%
9/5/2025 UpgradeModerate Buy
2/13/2025 UpgradeHold ➝ Buy$108.00+4.54%
2/12/2025Boost TargetOverweight$105.00 ➝ $110.00+6.33%
11/7/2024 Boost TargetNeutral$80.00 ➝ $95.00-2.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:11 PM ET.


Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 24, 2026. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Gilead Sciences, Inc. recently agreed to acquire PepStar Therapeutics' investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash, which strengthens the company's inflammation pipeline and positions it to compete in the inflammatory bowel disease market alongside its own emvistegrast asset.
  • The company is currently trading at $156.04, a level that reflects a significant year-to-date gain of 28.32% and a 90-day return of 20.67%, indicating strong recent momentum and sustained investor confidence in its biopharmaceutical portfolio.
  • Analysts maintain a Moderate Buy consensus with a price target of $159.63, and recent updates from firms like Erste Group Bank and TD Cowen suggest that Gilead Sciences, Inc. is well-positioned to meet or exceed earnings expectations, supported by a robust pipeline that includes new data on rare liver diseases to be presented at The Liver Meeting 2026.
  • Institutional interest in the stock has surged, with Sterling Capital Management LLC increasing its holdings by 1,584.4% in the third quarter and Royal Fund Management LLC raising its stake by 827.4%, signaling that large investors are accumulating shares in anticipation of future growth.
  • Gilead Sciences, Inc. is expanding its oncology and HIV franchises through strategic collaborations, such as a global Phase 3 trial with BioNTech for advanced triple-negative breast cancer and ongoing studies for a weekly oral HIV treatment, which diversifies revenue streams and supports long-term revenue durability.

Gilead Sciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • The company faces a negative price-to-earnings ratio of -58.44, which indicates that it is currently reporting a net loss, a situation that can deter value-oriented investors and suggests that profitability is not yet consistent with its market valuation.
  • Gilead Sciences, Inc. is required to pay a $45 million settlement to resolve Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines, which introduces regulatory and reputational risks that could impact future operations and investor sentiment.
  • Insider selling has been consistent and significant, with CEO Daniel O'Day selling 15,000 shares in October 2026 and CFO Andrew Dickinson selling 3,000 shares in the same period, which may signal that company executives are taking advantage of the recent stock price appreciation to reduce their personal exposure.
  • Some analysts, such as those from Zacks Research, have recently lowered their estimates for the stock, with one team estimating a negative value of -7 in May 2026, reflecting concerns about the company's ability to sustain its recent growth trajectory and manage its financial performance.
  • The stock's beta of 0.31 suggests it is less volatile than the broader market, but this also means it may underperform during strong market rallies, and the current price of $156.04 is close to its 52-week high of $160.51, leaving limited short-term upside before potential resistance levels are tested.

GILD Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $159.81, with a high forecast of $185.00 and a low forecast of $126.00.

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 6 hold ratings and 23 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted upside of 2.42% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 2 upgrades and 2 downgrades by analysts.

Analysts like Gilead Sciences more than other "healthcare" companies. The consensus rating for Gilead Sciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how GILD compares to other companies.


MarketBeat monitors more than a dozen sources for Gilead Sciences analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners